Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Zemaira Clears FDA; Aventis Behring Seeks Distribution Partner

  • News

Executive Summary

Aventis Behring is looking externally to boost the sales force for its Zemaira alpha-1 proteinase inhibitor

You may also be interested in...



Zemaira Convention Promotions Omit Risk Information, CBER Letter Says

ZLB Behring is requesting a meeting with CBER's advertising branch after receiving a warning letter citing Zemaira promotions used at a medical convention

Zemaira Convention Promotions Omit Risk Information, CBER Letter Says

ZLB Behring is requesting a meeting with CBER's advertising branch after receiving a warning letter citing Zemaira promotions used at a medical convention

Aventis Divests Behring: CSL Enters Factor VIII Market In $925 Mil. Deal

CSL will enter the U.S. Factor VIII market though its acquisition of Aventis Behring in a deal worth up to $925 mil

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

See All
UsernamePublicRestriction

Register

PS042143

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By